Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.40 |
| ▸ | CHUK | O15111 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14048973 | 0.91 | OPRM1 (0.43) | MAPTOPRM1MEN1POLBKMT2A | |
| SCHEMBL13093691 | 0.90 | OPRM1 (0.41) | IKBKBKDM4ENPC1MAPTRAB9A | |
| SCHEMBL14049089 | 0.90 | OPRD1 (0.36) | IKBKBOPRM1MEN1POLBKMT2A | |
| SCHEMBL14136645 | 0.89 | PTPN1 (0.41) | IKBKBKDM4ENPC1MAPTRAB9A | |
| SCHEMBL14049090 | 0.89 | IKBKB (0.42) | IKBKBKDM4ENPC1MAPTRAB9A | |
| SCHEMBL14049055 | 0.88 | ALDH1A1 (0.44) | IKBKBKDM4ENPC1MAPTRAB9A | |
| SCHEMBL14136625 | 0.87 | CHEK1 (0.35) | OPRM1 | |
| SCHEMBL2871039 | 0.85 | IKBKB (0.42) | IKBKBKDM4ENPC1MAPTRAB9A | |
| SCHEMBL14136642 | 0.83 | KDM4E (0.42) | KDM4ENPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL14048975 | 0.83 | KDM4E (0.42) | KDM4ENPC1MAPTRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269481-A1 | Compounds and methods for the treatment or prevention of Flavivirus infections | VIROCHEM PHARMA INC. (CA) | 2008-10-30 | — | — | US | disclosed |
| US-7402608-B2 | Compounds and methods for the treatment or prevention of Flavivirus infections | VIROCHEM PHARMA INC. (CA) | 2008-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269481-A1 | Compounds and methods for the treatment or prevention of Flavivirus infections | ZC3HAV1, ZYX, ZFX | IKBKB 994/4885KDM4E 1505/4885NPC1 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.